Clinical trial
NB1011 Administered by Continuous Infusion in Cancers That Overexpress…
NCT00248404 · Kiadis Pharma, Industry · Completed
Key facts
| NCT number | NCT00248404 |
|---|---|
| Title | NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) |
| Official title | A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase |
| Lead sponsor | Kiadis Pharma, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | NB1011 |
| Enrollment | 155 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 12, 2007 |
| Completion | Dec 12, 2007 |
| First posted | Nov 4, 2005 |
| Last update posted | May 16, 2022 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: